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Compared to the near Biblical reverence given to de Vita’s large
compendium Principles and Practice of Oncology, this 130 author,
64 chapter 897 page volume out of the same publishing stable is
probably somewhat less known to most cancer doctors whether
established or in training. As a life long devotee of ‘biotherapy’
during several of its peaks and troughs of interest over the last
25 years, I have to confess to having not read either its ﬁrst or
second editions from 1991 and did not have them available to
compare with the third edition, of which I have just completed a
detailed and highly educational read.
Mainstream oncologists treating the big four cancers, i.e. lung,
breast, colon and prostate, might at ﬁrst sight ﬁnd little to excite
them. This is because there have been so few studies of biotherapy
in these ﬁelds because they provide such a dominant market for
the palliative cytostatic chemotherapy and endocrine agents that
rarely produce durable complete remission. That the future in
breast and prostate cancer may be more interesting is raised by
observations from a small breast cancer study in Japan. This high-
lighted the fact that until that study which reported a doubling of
survival, none had examined biotherapy in combination with
endocrine therapy in patients with hormone sensitive cancer. All
previous reports from breast cancer were in patients treated after
escape from hormone control.
Another notable absence from this book are any studies on
combination between radiation and biotherapy apart from the
section on use of radio nucleotides to enhance activity of monoclo-
nal antibodies. This is clearly not due to omission, as there are no
recent studies, but because this discipline, focused by the need to
understand physics, has shown little interest in learning about this
area of biology. With anecdotal reports of patients loosing feet
from radiation induced arteritis after TNF limb perfusion treat-
ment, dying of acute encephalitis after brain radiation while
taking Interferon alpha and dying from exfoliative dermatitis after
wide ﬁeld low voltage radiation while taking interleukin-2, it is
clear that bio therapeutic drugs are rather powerful radiation sensi-
tizers and if used in smaller doses might improve local control.
With considerable progress being made with computerized confor-
mal radiation ﬁeld control this could be an important area for the
future in many ﬁelds including the common adult solid cancers
such as lung, rectal and prostate cancer.
The book itself is a real gold mine of information albeit from an
American perspective, covering all of the most signiﬁcant studies of
the last 15 years with data on more than 6000 patients in cytokine
trials (12–26% response 2–5% for greater than 5–10 years), 750
in cell therapy trials (mostly not an improvement though recent
trials with mini-allographs achieving 40% responses), 1400 in trials
of monoclonal antibodies (11–46% response), 128 in gene therapy
studies (mostly in progress though three reported an 8–22%
response) and more than 300 patients measurable disease phase 2
studies of experimental tumour vaccines (21% responses) and as
yet no data in a multiplicity of trials of antiangiogenic drugs
now underway. By providing such extensive overview data, the
need for more systematic analysis with longer follow up of these
trials is becoming apparent. This is because late follow up is
conﬁrming the early indications of durable complete remissions
that are long lasting with patients now regularly alive disease free
for more than 10 years, albeit only 2–5% of the original cases.
Moreover improved prognostication for response is helping to be
more focused in patient selection. However this is one area where
there could be even more improvement from advances in DNA,
RNA and protein typing that has already provided such improved
prognostication in other tumour sites. Success with such prognos-
tication might also ultimately facilitate ways of identifying
biotherapy sensitive minority of patients with the common cancers
not currently treated with biotherapy.
While the cytokine chapters are dominated by studies in Mela-
noma and Renal Cell Cancer on interferon and interleukin-2 and
the debates on whether high dose IL-2 is really better than low
dose IL-2 or single agent interferon, they provide little discussion
on the failure to improve on the results of monotherapy by
combining agents as had been shown in animal studies. The chap-
ters on IL-4, TNF, IL-12, gamma Interferon and gene therapy
highlight additional areas where encouraging animal studies have
failed to deliver clinical gain. However each of these chapters
provides hope for new gains in the future. Most exciting of these
undoubtedly is the chapter on Tumour necrosis factor alpha.
Almost certainly this cytokine was the mediator of the minority
of durable complete responses reported by Coley from use of
bacterial endotoxin in the early part of the 19th century. Despite
this, the initial results from TNF phase 1 studies were abysmal with
2.2% response in 566 patients treated in a multitude of different
schedules. However reports from its use intraperitoneally to
manage ascites in a series of 79 patients with 71% improvement,
taken with results from those on 111 melanoma patients and 309
sarcoma treatment with intra-arterial limb perfusion with melapha-
lan and TNF (+ gamma Interferon) with 79 and 33% local
complete response provide a model that may be relevant for
improving the results of local control of all solid cancer surgery
and also radiotherapy if the anecdotal report of enhanced vascular
damage proves generalizeable.
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ﬁed vaccines were equally disappointing to that on TNF
particularly so given the amount of hype there has been over the
area. However, one throw away line from the studies of intra-
tumoural p53 in lung cancer provides an assurance that there could
be more to come. This observation was the fact that in the trials of
intratumoural injection of p53 in lung cancer there were post
mortem studies showing complete remission in tumour injected
via the bronchoscope. Furthermore, though the overall response
rate in these studies was 20% in 25 cases and fell from 33% in
the phase 1 to 13% in the phase 2, more signiﬁcant was the fact
that six of the 12 patients who had collapsed lung from bronchial
obstruction had seen sufﬁcient tumour shrinkage to enable re-
expansion of the lung. Like the studies on TNF arterial perfusion
this data is highlighting the potential for highly selective therapy
to be focused on the primary tumour with the possibility of achiev-
ing durable complete remissions in a high proportion of patients
and improving local control.
Two other areas of particular interest emerge from the extensive
data brought together in this volume. The ﬁrst relates to the treat-
ment of follicular lymphoma. Despite this cancer having a
reputation for indolence such that observation can occasionally
be justiﬁed as primary management because of a spontaneous
regression rate of 25% and also having one of the highest responses
even after failed chemotherapy to interferon alpha (30–40%), to
IL-2 (26%) and to monoclonal antibodies such as the B lympho-
cyte antigen anti CD20 (53%), the only ﬁrst line studies are of
its use in combination with chemotherapy.
The ﬁnal area of interest raised by this book is the question of
use of erythropoietin in cancer patients. While few can dispute the
quality of life gain from reduction of tiredness on chemotherapy, it
is unlikely to increase long term cure or be a routine for any but
the most well funded services. Far more interesting and as yet
unresolved is the question whether there is any place to justify
use of this cytokine to treat the anaemia which is found in patients
with advanced cancer to improve their chances of responding to
standard treatment. There are two situations already providing
strong justiﬁcation for this thought. Firstly there are trials in cervix
cancer patients undergoing treatment with radiation aimed to
reduce tumour hypoxia. Secondly there is in vitro evidence that
erythropoietin treatment of cancer cell lines can enhance killing
by immune cells.
From this brief review it is clear that this book brings together a
body of data that has accumulated from a wide range of sources
that suggests biotherapy has a wider importance than is generally
appreciated by physicians and surgeons involved in treatment of
cancer patients. As a consequence there could be a case for this
volume to be as much compulsory reading as its companion on
Principles and Practice of Oncology for all trainees in ﬁelds
involved in care of cancer patients.
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